Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
A randomized discontinuation phase II study of sorafenib vs placebo in patients with non-small cell lung cancer (NSCLC) who failed at least two prior chemotherapy regimens: E2501 Schiller, J., Lee, J., Hanna, N. H., Traynor, A. M., Wakelee, H., Carbone, D. P. LIPPINCOTT WILLIAMS & WILKINS. 2009: S355–S356
View details for Web of Science ID 000269496001086